Patient Education & Adherence Flashcards

A patient with diabetes and high ASCVD risk asks why their LDL-C goal is lower than their neighbor's without diabetes. What is the best explanation?

Answer: Diabetes with ASCVD confers very high risk, requiring an LDL-C goal of <55 mg/dL per ACC/AHA guidelines

Diabetes with established ASCVD places patients in the very high-risk category, requiring more aggressive LDL-C targets (<55 mg/dL per 2022 ACC guidelines).

Which of the following best describes the concept of 'therapeutic inertia' in lipid management?

Answer: Failure of clinicians to intensify therapy when patients are not at guideline-recommended lipid goals

Therapeutic inertia refers to clinician failure to escalate lipid therapy even when treatment goals are unmet.

A patient asks if grapefruit juice is safe to consume while taking atorvastatin. What is the correct counseling?

Answer: Large quantities of grapefruit juice can inhibit CYP3A4 and increase atorvastatin levels, raising myopathy risk

Grapefruit inhibits CYP3A4, increasing plasma levels of CYP3A4-metabolized statins like atorvastatin, simvastatin, and lovastatin.

During motivational interviewing for statin adherence, what is the clinician's primary role?

Answer: To elicit the patient's own motivations for change and resolve ambivalence collaboratively

Motivational interviewing is patient-centered, eliciting the patient's intrinsic motivations rather than using persuasion or education alone.

A patient taking niacin for low HDL reports significant flushing. What patient education approach best improves tolerability?

Answer: Recommend taking aspirin 30 minutes before niacin and gradually titrating the dose

Pre-treatment with aspirin blunts prostaglandin-mediated flushing, and slow dose titration improves niacin tolerability.

Which of the following best supports long-term behavior change for dietary adherence in a patient with hyperlipidemia?

Answer: Setting small, achievable dietary goals that align with the patient's food preferences and culture

Small, culturally appropriate, and patient-centered dietary goals are associated with better long-term adherence than rigid universal prescriptions.

A patient on evolocumab (PCSK9 inhibitor) reports their LDL-C is now 18 mg/dL and asks if it is dangerously low. What is the most accurate response?

Answer: Very low LDL-C levels achieved with PCSK9 inhibitors have not been associated with significant safety concerns in clinical trials

FOURIER and ODYSSEY OUTCOMES trials demonstrated that very low LDL-C levels with PCSK9 inhibitors are safe, with further ASCVD risk reduction.